15 results on '"Fundación Eugenio Rodríguez Pascual"'
Search Results
2. Medium-term antifungal effects of methylene blue versus flavin mononucleotide in the treatment of moderate toenail onychomycosis
- Author
-
Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), Universidad Complutense de Madrid, Gómez, C. [0000-0002-5265-2233], Gómez, C., Schuele, Georg, Alberdi, Enrique, Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), Universidad Complutense de Madrid, Gómez, C. [0000-0002-5265-2233], Gómez, C., Schuele, Georg, and Alberdi, Enrique
- Abstract
Methylene blue (MB) and flavin mononucleotide (FMN)-mediated photodynamic therapy (PDT) have demonstrated local antimicrobial effect, but no direct comparative study has been published so far for the treatment of toenail onychomycosis.
- Published
- 2024
3. Fractional Laser for Ablative Resurfacing in Onychomycosis
- Author
-
Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), Gómez, C., Alberdi, E., Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), Gómez, C., and Alberdi, E.
- Published
- 2024
4. Urea versus fractional Er:YAG laser pretreatment of methylene blue photodynamic therapy in the treatment of moderate toenail onychomycosis: short- and medium-term effects
- Author
-
Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), CSIC - Unidad de Recursos de Información Científica para la Investigación (URICI), Alberdi, Enrique, Gómez, C., Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), CSIC - Unidad de Recursos de Información Científica para la Investigación (URICI), Alberdi, Enrique, and Gómez, C.
- Abstract
Keratolytic properties of urea 40% have long time used for the treatment of onychomycosis. Fractional ablative lasers enhance the delivery of topically applied photosensitizers improving photodynamic therapy (PDT) efficacy. The aim of this study was to compare the short- and medium-term efficacy of a pretreatment with urea 40% and fractional Er:YAG (Fr Er:YAG) laser radiation before PDT mediated by methylene blue (MB) for moderate toenail onychomycosis. Twenty-first-toe toenails were randomized to receive either urea 40% (Group I) or Fr Er:YAG laser (Group II) pretreatment and 9 sessions of MB/PDT over the course of 16 weeks. At baseline, 28- and 40-week follow-ups, clinical efficacy was assessed by digital photographs [allowing determination of the onychomycosis severity index (OSI)], whereas mycological efficacy was assessed by histological examination and fungal culture. Details of the side effects and patients' satisfaction were also recorded. In both groups, a significant decrease in OSI values was observed at the 28-week follow-up and a slight rebound at the 40-week follow-up. The percentage of nail involvement decreased significantly in both groups at the 28-week follow-up, to continue declining gently in Group I at 40 weeks, in contrast to the rebound observed during this period in Group II. The mycological cure rate was 20% and 30% at 28-week follow-up and 70% and 40% at 40-week follow-up, in Group I and II, respectively. Patients reported being fairly satisfied, and no side effects were detected in any groups. Although both pretreatments favor the action of PDT for the treatment of onychomycosis, the use of urea at 40% is more effective in the medium term.
- Published
- 2023
5. SPINOPHILIN: A multiplayer tumor suppressor
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Asociación Española Contra el Cáncer, Fundación Eugenio Rodríguez Pascual, Ministerio de Economía y Competitividad (España), Verdugo-Sivianes, Eva M., Carnero, Amancio, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Asociación Española Contra el Cáncer, Fundación Eugenio Rodríguez Pascual, Ministerio de Economía y Competitividad (España), Verdugo-Sivianes, Eva M., and Carnero, Amancio
- Abstract
SPINOPHILIN (SPN, PPP1R9B or NEURABIN-2) is a multifunctional protein that regulates protein–protein interactions in different cell signaling pathways. SPN is also one of the regulatory subunits of protein phosphatase 1 (PP1), implicated in the dephosphorylation of retinoblastoma protein (pRB) during cell cycle. The SPN gene has been described as a tumor suppressor in different human tumor contexts, in which low levels of SPN are correlated with a higher grade and worse prognosis. In addition, mutations of the SPN protein have been reported in human tumors. Recently, an oncogenic mutation of SPN, A566V, was described, which affects both the SPN–PP1 interaction and the phosphatase activity of the holoenzyme, and promotes p53-dependent tumorigenesis by increasing the cancer stem cell (CSC) pool in breast tumors. Thus, the loss or mutation of SPN could be late events that promotes tumor progression by increasing the CSC pool and, eventually, the malignant behavior of the tumor.
- Published
- 2023
6. REDOX Balance in Oligodendrocytes Is Important for Zebrafish Visual System Regeneration
- Author
-
Universidad de Salamanca, Fundación Eugenio Rodríguez Pascual, European Commission, Consejo Superior de Investigaciones Científicas (España), Junta de Castilla y León, Agencia Estatal de Investigación (España), Ministerio de Ciencia e Innovación (España), Sociedad Española de Bioquímica y Biología Molecular, Sociedad Española de Autofagia, Pérez-Montes, Cristina [0000-0003-1195-9367], García-Macia, Marina [0000-0002-3908-9060], Pérez-Montes, Cristina, Jiménez-Cubides, Jhoana Paola, Velasco, Almudena, Arévalo, Rosario, Santos-Ledo, Adrián, García-Macia, Marina, Universidad de Salamanca, Fundación Eugenio Rodríguez Pascual, European Commission, Consejo Superior de Investigaciones Científicas (España), Junta de Castilla y León, Agencia Estatal de Investigación (España), Ministerio de Ciencia e Innovación (España), Sociedad Española de Bioquímica y Biología Molecular, Sociedad Española de Autofagia, Pérez-Montes, Cristina [0000-0003-1195-9367], García-Macia, Marina [0000-0002-3908-9060], Pérez-Montes, Cristina, Jiménez-Cubides, Jhoana Paola, Velasco, Almudena, Arévalo, Rosario, Santos-Ledo, Adrián, and García-Macia, Marina
- Abstract
Zebrafish (Danio rerio) present continuous growth and regenerate many parts of their body after an injury. Fish oligodendrocytes, microglia and astrocytes support the formation of new connections producing effective regeneration of the central nervous system after a lesion. To understand the role of oligodendrocytes and the signals that mediate regeneration, we use the well-established optic nerve (ON) crush model. We also used sox10 fluorescent transgenic lines to label fully differentiated oligodendrocytes. To quench the effect of reactive oxygen species (ROS), we used the endogenous antioxidant melatonin. Using these tools, we measured ROS production by flow cytometry and explored the regeneration of the optic tectum (OT), the response of oligodendrocytes and their mitochondria by confocal microscopy and Western blot. ROS are produced by oligodendrocytes 3 h after injury and JNK activity is triggered. Concomitantly, there is a decrease in the number of fully differentiated oligodendrocytes in the OT and in their mitochondrial population. By 24 h, oligodendrocytes partially recover. Exposure to melatonin blocks the changes observed in these oligodendrocytes at 3 h and increases their number and their mitochondrial populations after 24 h. Melatonin also blocks JNK upregulation and induces aberrant neuronal differentiation in the OT. In conclusion, a proper balance of ROS is necessary during visual system regeneration and exposure to melatonin has a detrimental impact.
- Published
- 2023
7. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma
- Author
-
Instituto de Salud Carlos III, Junta de Castilla y León, Fundación Ramón Areces, Fundación Memoria de D. Samuel Solorzano Barruso, Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Baltanás, Fernando C., García-Navas, Rósula, Rodríguez-Ramos, Pablo, Calzada, Nuria, Cuesta, Cristina, Borrajo, Javier, Fuentes-Mateos, Rocío, Olarte-San Juan, Andrea, Vidaña-Bedera, Nerea, Castellano, Esther, Santos de Dios, Eugenio, Instituto de Salud Carlos III, Junta de Castilla y León, Fundación Ramón Areces, Fundación Memoria de D. Samuel Solorzano Barruso, Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Baltanás, Fernando C., García-Navas, Rósula, Rodríguez-Ramos, Pablo, Calzada, Nuria, Cuesta, Cristina, Borrajo, Javier, Fuentes-Mateos, Rocío, Olarte-San Juan, Andrea, Vidaña-Bedera, Nerea, Castellano, Esther, and Santos de Dios, Eugenio
- Abstract
The impact of genetic ablation of SOS1 or SOS2 is evaluated in a murine model of KRASG12D-driven lung adenocarcinoma (LUAD). SOS2 ablation shows some protection during early stages but only SOS1 ablation causes significant, specific long term increase of survival/lifespan of the KRASG12D mice associated to markedly reduced tumor burden and reduced populations of cancer-associated fibroblasts, macrophages and T-lymphocytes in the lung tumor microenvironment (TME). SOS1 ablation also causes specific shrinkage and regression of LUAD tumoral masses and components of the TME in pre-established KRASG12D LUAD tumors. The critical requirement of SOS1 for KRASG12D-driven LUAD is further confirmed by means of intravenous tail injection of KRASG12D tumor cells into SOS1KO/KRASWT mice, or of SOS1-less, KRASG12D tumor cells into wildtype mice. In silico analyses of human lung cancer databases support also the dominant role of SOS1 regarding tumor development and survival in LUAD patients. Our data indicate that SOS1 is critically required for development of KRASG12D-driven LUAD and confirm the validity of this RAS-GEF activator as an actionable therapeutic target in KRAS mutant LUAD.
- Published
- 2023
8. Senotherapeutics in Cancer and HIV
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Fundación Eugenio Rodríguez Pascual, Fundación Científica Asociación Española Contra el Cáncer, Sánchez-Díaz, Laura, Espinosa-Sánchez, Asunción, Blanco, José Ramón, Carnero, Amancio, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Fundación Eugenio Rodríguez Pascual, Fundación Científica Asociación Española Contra el Cáncer, Sánchez-Díaz, Laura, Espinosa-Sánchez, Asunción, Blanco, José Ramón, and Carnero, Amancio
- Abstract
Cellular senescence is a stress-response mechanism that contributes to homeostasis maintenance, playing a beneficial role during embryogenesis and in normal adult organisms. In contrast, chronic senescence activation may be responsible for other events such as age-related disorders, HIV and cancer development. Cellular senescence activation can be triggered by different insults. Regardless of the inducer, there are several phenotypes generally shared among senescent cells: cell division arrest, an aberrant shape, increased size, high granularity because of increased numbers of lysosomes and vacuoles, apoptosis resistance, defective metabolism and some chromatin alterations. Senescent cells constitute an important area for research due to their contributions to the pathogenesis of different diseases such as frailty, sarcopenia and aging-related diseases, including cancer and HIV infection, which show an accelerated aging. Hence, a new pharmacological category of treatments called senotherapeutics is under development. This group includes senolytic drugs that selectively attack senescent cells and senostatic drugs that suppress SASP factor delivery, inhibiting senescent cell development. These new drugs can have positive therapeutic effects on aging-related disorders and act in cancer as antitumor drugs, avoiding the undesired effects of senescent cells such as those from SASP. Here, we review senotherapeutics and how they might affect cancer and HIV disease, two very different aging-related diseases, and review some compounds acting as senolytics in clinical trials.
- Published
- 2022
9. 3D and organoid culture in research: physiology, hereditary genetic diseases and cancer
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Asociación Española Contra el Cáncer, Fundación Eugenio Rodríguez Pascual, Carnero, Amancio [0000-0003-4357-3979], Suarez-Martinez, Elisa, Suazo-Sánchez, Irene, Celis-Romero, Manuel, Carnero, Amancio, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Asociación Española Contra el Cáncer, Fundación Eugenio Rodríguez Pascual, Carnero, Amancio [0000-0003-4357-3979], Suarez-Martinez, Elisa, Suazo-Sánchez, Irene, Celis-Romero, Manuel, and Carnero, Amancio
- Abstract
In nature, cells reside in tissues subject to complex cell-cell interactions, signals from extracellular molecules and niche soluble and mechanical signaling. These microenvironment interactions are responsible for cellular phenotypes and functions, especially in normal settings. However, in 2D cultures, where interactions are limited to the horizontal plane, cells are exposed uniformly to factors or drugs; therefore, this model does not reconstitute the interactions of a natural microenvironment. 3D culture systems more closely resemble the architectural and functional properties of in vivo tissues. In these 3D cultures, the cells are exposed to different concentrations of nutrients, growth factors, oxygen or cytotoxic agents depending on their localization and communication. The 3D architecture also differentially alters the physiological, biochemical, and biomechanical properties that can affect cell growth, cell survival, differentiation and morphogenesis, cell migration and EMT properties, mechanical responses and therapy resistance. This latter point may, in part, explain the failure of current therapies and affect drug discovery research. Organoids are a promising 3D culture system between 2D cultures and in vivo models that allow the manipulation of signaling pathways and genome editing of cells in a body-like environment but lack the many disadvantages of a living system. In this review, we will focus on the role of stem cells in the establishment of organoids and the possible therapeutic applications of this model, especially in the field of cancer research.
- Published
- 2022
10. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors
- Author
-
Junta de Andalucía, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Ministerio de Educación, Cultura y Deporte (España), EMBO, Grupo Español de Tumores Neuroendocrinos y Endocrinos, Fundación Eugenio Rodríguez Pascual, Medical Research Council (UK), Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (España), Ibáñez-Costa, Alejandro [0000-0003-4649-0095], Gahete, Manuel D. [0000-0002-4578-2179], Castaño, Justo P. [0000-0002-3145-7287], Pedraza-Arévalo, Sergio, Ibáñez-Costa, Alejandro, Blázquez-Encinas, Ricardo, Branco, Miguel R., Vázquez-Borrego, Mari C., Herrera-Martínez, Aura D., Venegas Moreno, Eva, Serrano-Blanch, Raquel, Arjona-Sánchez, Álvaro, Gálvez-Moreno, María Ángeles, Korbonits, Marta, Soto-Moreno, Alfonso, Gahete, Manuel D., Charalambous, Marika, Luque, Raúl M., Castaño, Justo P., Junta de Andalucía, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Ministerio de Educación, Cultura y Deporte (España), EMBO, Grupo Español de Tumores Neuroendocrinos y Endocrinos, Fundación Eugenio Rodríguez Pascual, Medical Research Council (UK), Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (España), Ibáñez-Costa, Alejandro [0000-0003-4649-0095], Gahete, Manuel D. [0000-0002-4578-2179], Castaño, Justo P. [0000-0002-3145-7287], Pedraza-Arévalo, Sergio, Ibáñez-Costa, Alejandro, Blázquez-Encinas, Ricardo, Branco, Miguel R., Vázquez-Borrego, Mari C., Herrera-Martínez, Aura D., Venegas Moreno, Eva, Serrano-Blanch, Raquel, Arjona-Sánchez, Álvaro, Gálvez-Moreno, María Ángeles, Korbonits, Marta, Soto-Moreno, Alfonso, Gahete, Manuel D., Charalambous, Marika, Luque, Raúl M., and Castaño, Justo P.
- Abstract
Somatostatin receptor subtype 5 (SST5 ) is an emerging biomarker and actionable target in pituitary (PitNETs) and pancreatic (PanNETs) neuroendocrine tumors. Transcriptional and epigenetic regulation of SSTR5 gene expression and mRNA biogenesis is poorly understood. Recently, an overlapping natural antisense transcript, SSTR5-AS1, potentially regulating SSTR5 expression, was identified. We aimed to elucidate whether epigenetic processes contribute to the regulation of SSTR5 expression in PitNETs (somatotropinomas) and PanNETs. We analyzed the SSTR5/SSTR5-AS1 human locus in silico to identify CpG islands. SSTR5 and SSTR5-AS1 expression was assessed by quantitative real-time PCR (qPCR) in 27 somatotropinomas, 11 normal pituitaries (NPs), and 15 PanNETs/paired adjacent (control) samples. We evaluated methylation grade in four CpG islands in the SSTR5/SSTR5-AS1 genes. Results revealed that SSTR5 and SSTR5-AS1 were directly correlated in NP, somatotropinoma, and PanNET samples. Interestingly, selected CpG islands were differentially methylated in somatotropinomas compared with NPs. In PanNETs cell lines, SSTR5-AS1 silencing downregulated SSTR5 expression, altered aggressiveness features, and influenced pasireotide response. These results provide evidence that SSTR5 expression in PitNETs and PanNETs can be epigenetically regulated by the SSTR5-AS1 antisense transcript and, indirectly, by DNA methylation, which may thereby impact tumor behavior and treatment response.
- Published
- 2022
11. Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets
- Author
-
Comunidad de Madrid, Fundación Mutua Madrileña, Bayer Healthcare, Fundación Eugenio Rodríguez Pascual, Merck Serono, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Paz-Cabezas, Mateo, Calvo-López, Tania, Romera-Lopez, Alejandro, Tabas-Madrid, Daniel, Ogando, Jesús, Fernández-Aceñero, María-Jesús, Sastre, Javier, Pascual-Montano, Alberto, Mañes, Santos, Díaz-Rubio, Eduardo, Pérez Villamil, Beatriz, Comunidad de Madrid, Fundación Mutua Madrileña, Bayer Healthcare, Fundación Eugenio Rodríguez Pascual, Merck Serono, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Paz-Cabezas, Mateo, Calvo-López, Tania, Romera-Lopez, Alejandro, Tabas-Madrid, Daniel, Ogando, Jesús, Fernández-Aceñero, María-Jesús, Sastre, Javier, Pascual-Montano, Alberto, Mañes, Santos, Díaz-Rubio, Eduardo, and Pérez Villamil, Beatriz
- Abstract
Colorectal cancer consensus molecular subtypes (CMSs) are widely accepted and constitutes the basis for patient stratification to improve clinical practice. We aimed to find whether miRNAs could reproduce molecular subtypes, and to identify miRNA targets associated to the High-stroma/CMS4 subtype. The expression of 939 miRNAs was analyzed in tumors classified in CMS. TALASSO was used to find gene-miRNA interactions. A miR-mRNA regulatory network was constructed using Cytoscape. Candidate gene-miR interactions were validated in 293T cells. Hierarchical-Clustering identified three miRNA tumor subtypes (miR-LS; miR-MI; and miR-HS) which were significantly associated (p < 0.001) to the reported mRNA subtypes. miR-LS correlated with the low-stroma/CMS2; miR-MI with the mucinous-MSI/CMS1 and miR-HS with high-stroma/CMS4. MicroRNA tumor subtypes and association to CMSs were validated with TCGA datasets. TALASSO identified 1462 interactions (p < 0.05) out of 21,615 found between 176 miRs and 788 genes. Based on the regulatory network, 88 miR-mRNA interactions were selected as candidates. This network was functionally validated for the pair miR-30b/SLC6A6. We found that miR-30b overexpression silenced 3′-UTR-SLC6A6-driven luciferase expression in 293T-cells; mutation of the target sequence in the 3′-UTR-SLC6A6 prevented the miR-30b inhibitory effect. In conclusion CRC subtype classification using a miR-signature might facilitate a real-time analysis of the disease course and treatment response.
- Published
- 2022
12. Urea versus fractional Er:YAG laser pretreatment of methylene blue photodynamic therapy in the treatment of moderate toenail onychomycosis: short- and medium-term effects
- Author
-
Enrique Alberdi, Clara Gómez, Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia e Innovación (España), and CSIC - Unidad de Recursos de Información Científica para la Investigación (URICI)
- Subjects
Methylene blue ,Onychomycosis ,Dermatology ,General Medicine ,Fractional Er:YAG laser ,Photodynamic therapy - Abstract
8 pags., 2 figs., 2 tabs., Keratolytic properties of urea 40% have long time used for the treatment of onychomycosis. Fractional ablative lasers enhance the delivery of topically applied photosensitizers improving photodynamic therapy (PDT) efficacy. The aim of this study was to compare the short- and medium-term efficacy of a pretreatment with urea 40% and fractional Er:YAG (Fr Er:YAG) laser radiation before PDT mediated by methylene blue (MB) for moderate toenail onychomycosis. Twenty-first-toe toenails were randomized to receive either urea 40% (Group I) or Fr Er:YAG laser (Group II) pretreatment and 9 sessions of MB/PDT over the course of 16 weeks. At baseline, 28- and 40-week follow-ups, clinical efficacy was assessed by digital photographs [allowing determination of the onychomycosis severity index (OSI)], whereas mycological efficacy was assessed by histological examination and fungal culture. Details of the side effects and patients' satisfaction were also recorded. In both groups, a significant decrease in OSI values was observed at the 28-week follow-up and a slight rebound at the 40-week follow-up. The percentage of nail involvement decreased significantly in both groups at the 28-week follow-up, to continue declining gently in Group I at 40 weeks, in contrast to the rebound observed during this period in Group II. The mycological cure rate was 20% and 30% at 28-week follow-up and 70% and 40% at 40-week follow-up, in Group I and II, respectively. Patients reported being fairly satisfied, and no side effects were detected in any groups. Although both pretreatments favor the action of PDT for the treatment of onychomycosis, the use of urea at 40% is more effective in the medium term., This research was supported by a grant from the Eugenio Rodríguez Pascual Foundation (Madrid, Spain) and by the Spanish Research Project MICINN (Ref.:PiD2020-114755GB-C31). Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.
- Published
- 2022
- Full Text
- View/download PDF
13. Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST5) in pituitary and pancreatic neuroendocrine tumors
- Author
-
Alfonso Soto-Moreno, Miguel R. Branco, Marika Charalambous, Mari C Vázquez-Borrego, Eva Venegas-Moreno, Manuel D. Gahete, María A Gálvez-Moreno, Sergio Pedraza-Arevalo, Alejandro Ibáñez-Costa, Raquel Serrano-Blanch, Aura D. Herrera-Martínez, Álvaro Arjona-Sánchez, Raúl M. Luque, Justo P. Castaño, Ricardo Blazquez-Encinas, Márta Korbonits, Junta de Andalucía, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Ministerio de Educación, Cultura y Deporte (España), EMBO, Grupo Español de Tumores Neuroendocrinos y Endocrinos, Fundación Eugenio Rodríguez Pascual, Medical Research Council (UK), Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (España), Ibáñez-Costa, Alejandro, Gahete, Manuel D., and Castaño, Justo P.
- Subjects
Cancer Research ,natural antisense transcript ,Biology ,pituitary ,Epigenesis, Genetic ,Genetics ,Gene silencing ,Humans ,Pituitary Neoplasms ,Epigenetics ,Receptors, Somatostatin ,pancreas ,Post-transcriptional regulation ,RC254-282 ,epigenetics ,Somatostatin receptor ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,Methylation ,DNA Methylation ,Antisense RNA ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,SST5 ,Oncology ,CpG site ,DNA methylation ,Cancer research ,Molecular Medicine ,neuroendocrine tumors - Abstract
Somatostatin receptor subtype 5 (SST5 ) is an emerging biomarker and actionable target in pituitary (PitNETs) and pancreatic (PanNETs) neuroendocrine tumors. Transcriptional and epigenetic regulation of SSTR5 gene expression and mRNA biogenesis is poorly understood. Recently, an overlapping natural antisense transcript, SSTR5-AS1, potentially regulating SSTR5 expression, was identified. We aimed to elucidate whether epigenetic processes contribute to the regulation of SSTR5 expression in PitNETs (somatotropinomas) and PanNETs. We analyzed the SSTR5/SSTR5-AS1 human locus in silico to identify CpG islands. SSTR5 and SSTR5-AS1 expression was assessed by quantitative real-time PCR (qPCR) in 27 somatotropinomas, 11 normal pituitaries (NPs), and 15 PanNETs/paired adjacent (control) samples. We evaluated methylation grade in four CpG islands in the SSTR5/SSTR5-AS1 genes. Results revealed that SSTR5 and SSTR5-AS1 were directly correlated in NP, somatotropinoma, and PanNET samples. Interestingly, selected CpG islands were differentially methylated in somatotropinomas compared with NPs. In PanNETs cell lines, SSTR5-AS1 silencing downregulated SSTR5 expression, altered aggressiveness features, and influenced pasireotide response. These results provide evidence that SSTR5 expression in PitNETs and PanNETs can be epigenetically regulated by the SSTR5-AS1 antisense transcript and, indirectly, by DNA methylation, which may thereby impact tumor behavior and treatment response., This research was funded by Junta de Andalucía (BIO-0139, P20_00442; PEER-0048-2020); Spanish Ministry of Economy (BFU2016-80360-R), Ministry of Science and Innovation (PID2019-105201RB-I00, PID2019-105564RB-I00); and ISCIII (PI16-00264, CD19/00255), co-funded with EU funds from FEDER Program. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under project WHRI-ACADEMY, REA grant agreement n° 608765; MECD (FPU14/04290, FPU18/02275); EMBO (short term fellowship 6802); GETNE G2019 Research Grant; Fundación Eugenio Rodriguez Pascual (FERP2019); project grants from the UK Medical Research Council (MR/R022836/1; MR/L002345/1); and CIBERobn; CIBER Fisiopatología de la Obesidad y Nutriciín is an initiative of Instituto de Salud Carlos III.
- Published
- 2022
14. Senotherapeutics in Cancer and HIV
- Author
-
Laura Sánchez-Díaz, Asunción Espinosa-Sánchez, José-Ramón Blanco, Amancio Carnero, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Fundación Eugenio Rodríguez Pascual, and Fundación Científica Asociación Española Contra el Cáncer
- Subjects
Aging ,Senotherapy ,senescence ,Senostatic ,HIV ,senotherapy ,HIV Infections ,General Medicine ,Senescence ,SASP ,senolytic ,senostatic ,Senotherapeutics ,Neoplasms ,cancer ,Humans ,Senolytic ,Cellular Senescence ,Cancer - Abstract
Cellular senescence is a stress-response mechanism that contributes to homeostasis maintenance, playing a beneficial role during embryogenesis and in normal adult organisms. In contrast, chronic senescence activation may be responsible for other events such as age-related disorders, HIV and cancer development. Cellular senescence activation can be triggered by different insults. Regardless of the inducer, there are several phenotypes generally shared among senescent cells: cell division arrest, an aberrant shape, increased size, high granularity because of increased numbers of lysosomes and vacuoles, apoptosis resistance, defective metabolism and some chromatin alterations. Senescent cells constitute an important area for research due to their contributions to the pathogenesis of different diseases such as frailty, sarcopenia and aging-related diseases, including cancer and HIV infection, which show an accelerated aging. Hence, a new pharmacological category of treatments called senotherapeutics is under development. This group includes senolytic drugs that selectively attack senescent cells and senostatic drugs that suppress SASP factor delivery, inhibiting senescent cell development. These new drugs can have positive therapeutic effects on aging-related disorders and act in cancer as antitumor drugs, avoiding the undesired effects of senescent cells such as those from SASP. Here, we review senotherapeutics and how they might affect cancer and HIV disease, two very different aging-related diseases, and review some compounds acting as senolytics in clinical trials., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00; grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejeria de Salud (PI-0397-2017) andProject P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Adalucia move with Europe. Additionally, we thank the Fundacion AECC and Fundacion Eugenio Rodriguez Pascual for supporting this work. LS-D and ES-M were funded by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE). AE-S was funded by Fundacion AECC.
- Published
- 2022
15. Novel indolic AMPK modulators induce vasodilatation through activation of the AMPK–eNOS–NO pathway
- Author
-
Marta Sanz-Gómez, Elnaz Aledavood, Marina Beroiz-Salaverri, Laura Lagartera, Elena Vega-Martín, Marta Gil-Ortega, Jose Cumella, Concepción Pérez, Francisco Javier Luque, Carolina Estarellas, María S. Fernández-Alfonso, Ana Castro, Fundación Eugenio Rodríguez Pascual, Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Generalitat de Catalunya, and Universidad Complutense de Madrid
- Subjects
Multidisciplinary ,Nitric Oxide Synthase Type III ,Endothelial Cells ,Enzyme inhibitors ,AMP-Activated Protein Kinases ,Nitric Oxide ,Rats ,Vasodilation ,Inhibidors enzimàtics ,Obesitat ,Animals ,Humans ,Endothelium, Vascular ,Obesity ,Phosphorylation ,Signal Transduction - Abstract
Endothelial adenosine monophosphate-activated protein kinase (AMPK) plays a critical role in the regulation of vascular tone through stimulating nitric oxide (NO) release in endothelial cells. Since obesity leads to endothelial dysfunction and AMPK dysregulation, AMPK activation might be an important strategy to restore vascular function in cardiometabolic alterations. Here, we report the identification of a novel AMPK modulator, the indolic derivative IND6, which shows affinity for AMPKα1β1γ1, the primary AMPK isoform in human EA.Hy926 endothelial cells. IND6 shows inhibitory action of the enzymatic activity in vitro, but increases the levels of p-Thr174AMPK, p-Ser1177eNOS and p-Ser79ACC in EA.Hy926. This paradoxical finding might be explained by the ability of IND6 to act as a mixed-type inhibitor, but also to promote the enzyme activation by adopting two distinct binding modes at the ADaM site. Moreover, functional assays reveal that IND6 increased the eNOS-dependent production of NO and elicited a concentration-dependent vasodilation of endothelium-intact rat aorta due to AMPK and eNOS activation, demonstrating a functional activation of the AMPK–eNOS–NO endothelial pathway. This kinase inhibition profile, combined with the paradoxical AMPK activation in cells and arteries, suggests that these new chemical entities may constitute a valuable starting point for the development of new AMPK modulators with therapeutic potential for the treatment of vascular complications associated with obesity., his research was funded by Fundación Eugenio Rodríguez Pascual, the Spanish Ministerio de Economía y Competitividad (MDM-2017-0767), the Spanish Ministerio de Ciencia Innovación y Universidades (RTI2018- 095544-B-I00) and the Generalitat de Catalunya (2017SGR1746) for financial support. Computational resources from the Barcelona Supercomputing Center (BSC; BCV-2019-1-0009 and BCV-2019-2-0017) and the Consorci de Serveis Universitaris de Catalunya (CSUC; Molecular Recognition project) are acknowledged. E.A. thanks AGAUR (Generalitat of Catalunya; 2019FI_B2_00001) for her fellowship. M.S.G. thanks Universidad Com- plutense de Madrid for her fellowship.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.